This review is particularly insightful as it found that another modern class of antidiabetic drugs, GLP-1 RA, was associated with a statistically significant reduction in dementia risk, suggesting that the statistically insignificant finding for SGLT2 inhibitors was not simply a feature of all modern antidiabetic therapies in these trials [2]. Here, SLC5A2 is linked to dementia.